drugset / Trial / NCT02583256

Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine in Children Previously Vaccinated in Trial V118_05 (NCT01964989)

NCT02583256 ↗

Phase 3 Completed 1601 enrolled Seqirus
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously vaccinated in Trial V118\_05. Subjects will receive either the Same or Alternate Type of Vaccine.

Timeline

Start
2016-01-29
Primary completion
2016-11-15
Completion
2017-05-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Adjuvanted QIV Vaccine — —
Subject Non-adjuvanted QIV Vaccine — —

Indications